Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Climb Bio, Inc. (CLYM : NSDQ)

• Company Description    Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass. Number of Employees: 18

• Price / Volume Information    Yesterday's Closing Price: $1.83 Daily Weekly Monthly 20 Day Moving Average: 898,318 shares Shares Outstanding: 68.18 (millions) Market Capitalization: $124.78 (millions) Beta: -0.06 52 Week High: $4.34 52 Week Low: $1.05 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 1.67% -1.00% 12 Week -3.68% -7.68% Year To Date 1.67% -11.13%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 20 William Street Suite 145 - Wellesley Hills,MA 02481 USA ph: 866-857-2596 fax: - investorrelations@climbbio.com http://www.eliemtx.com

• General Corporate Information    Officers Aoife Brennan - President and Chief Executive Officer Douglas E. Williams - Chairman Brett Kaplan - Chief Operating Officer Emily Pimblett - Chief Accounting Officer Andrew Levin - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 28658R106 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/24/26 Share - Related Items Shares Outstanding: 68.18 Most Recent Split Date: (:1) Beta: -0.06 Market Capitalization: $124.78 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.17 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.76 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/24/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.70 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -46.15% vs. Previous Quarter: -46.15% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/25 - -26.43 06/30/25 - -23.10 03/31/25 - -43.95 ROA 09/30/25 - -25.61 06/30/25 - -22.47 03/31/25 - -42.94 Current Ratio 09/30/25 - 18.38 06/30/25 - 14.08 03/31/25 - 14.25 Quick Ratio 09/30/25 - 18.38 06/30/25 - 14.08 03/31/25 - 14.25 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Book Value 09/30/25 - 2.61 06/30/25 - 2.75 03/31/25 - 2.86 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©